InvestorsHub Logo

MackG

02/21/21 7:50 AM

#347820 RE: loanranger #347817

Page 4 shows a precedent for a company in phase 2 getting more than a 25% royalty. With positive covid clinical trial results, Brilacidin would easily fit into that catagory given the massive revenue stream it would generate. Very nice.